
Masimo (MASI) Stock Forecast & Price Target
Masimo (MASI) Analyst Ratings
Bulls say
Masimo is a solid company with a focused approach on healthcare technology, and their strategic priorities including focus, innovation, and execution will continue to drive growth and profitability. They are also heavily invested in research and development, with over 80 studies planned in the next three years, which will contribute to future revenue growth. The recent agreement with Danaher for a $9.9B cash acquisition shows the value and potential of Masimo's business.
Bears say
Masimo is facing issues with predictable revenue due to fluctuations in installations and orders, as well as challenges with predicting quarterly revenue for their healthcare products. In comparison to other medical technology companies like Edwards Lifesciences Corporation and Intuitive Surgical, Inc., their financials and key metrics are relatively weaker, with slower integration of mergers and acquisitions, pricing pressure, and slower demand for capital equipment, making us have a negative outlook on the stock. However, risks to our rating and price target include unexpected positive announcements, potential improvements in competitive dynamics within the spine market, and better expense management, which could potentially increase the likelihood of achieving our $200 price target.
This aggregate rating is based on analysts' research of Masimo and is not a guaranteed prediction by Public.com or investment advice.
Masimo (MASI) Analyst Forecast & Price Prediction
Start investing in Masimo (MASI)
Order type
Buy in
Order amount
Est. shares
0 shares